BASi Reports First Quarter Net Income of $0.02 Per Share versus a Prior Year First Quarter Net Loss
BASi Reports First Quarter Net Income of $0.02 Per Share versus a Prior Year First Quarter Net Loss of $0.21 Per Share
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Bioanalytical Systems, Inc.
Revenue decreased to $5,803,000, compared to $7,516,000 for the first quarter of fiscal 2012. Gross margin improved to 32.0% of revenue, compared to 19.7% a year ago. Operating income for this year's first quarter increased to $302,000, versus an operating loss of $1,302,000 for the same period last year, driven by the increase in gross margin and a 44.2% reduction in operating expenses. Net income for the first quarter of fiscal 2013 was $139,000, or $0.02 per basic and diluted share. This compares to a net loss for the first quarter of fiscal 2012 of $1,491,000, or $0.21 per basic and diluted share.
EBITDA for this year's first quarter was $851,000, versus an EBITDA loss of $704,000 for the first quarter of fiscal 2012. Cash provided by operations was $702,000 for the first quarter of the current fiscal year, versus $590,000 a year ago.
President & CEO and CFO Jacqueline Lemke said, "With the notable exception of revenue, all of our operating metrics moved decisively in the right direction in the first quarter compared to prior year. We believe these improvements are sustainable. Now we are implementing a strategy to restore revenue growth that builds on BASi's competitive strengths - specialty assay and discovery capabilities, a long history of regulatory excellence, and our market-changing Culex NxT system. While it will take time for these initiatives to translate into higher sales for BASi, we expect to begin seeing positive results later this fiscal year.
"As we anticipated, our first quarter service revenue comparison was negatively affected by the consolidation of our Oregon laboratory into our West Lafayette facility and the closure of our UK lab in last year's second half. Service revenue in the current quarter was also impacted by unexpected delays in the start of certain pharmaceutical analysis contracts. Although product sales have historically been strongest in the first quarter of the fiscal year, it appears that customers delayed orders in anticipation of the launch of our new advanced Culex® NxT in vivo sampling system. Supporting this view, product orders have picked up in the past few weeks, which is an encouraging sign for the future.
"On the service side, we recently announced the first of a number of collaborative research projects and preferred provider partnerships that we expect to contribute to revenue beginning this fiscal year. Additionally, we currently are interviewing to hire both a West Coast and an East Coast bioanalytical services sales representative to improve our reach across the United States, and have realigned sales compensation to incentivize new sales and reward winning business based upon referrals and reputation. We remain optimistic about the outlook for fiscal 2013."
Balance Sheet Highlights
At December 31, 2012, BASi reported cash and cash equivalents of $670,000, total long-term obligations of $689,000, and shareholders' equity of $9,832,000. Current liabilities at December 31, 2012 included mortgage debt of $5,676,000 that matures in October 2013. The Company continues to explore ways to deal with this debt, including a sale leaseback transaction on its building in West Lafayette, Indiana. At September 30, 2012, cash and cash equivalents were $721,000, total long-term obligations were $5,998,000, and shareholders' equity was $9,590,000.
Earnings Conference Call
BASi has scheduled a conference call at 11:00 a.m. EST this morning to discuss its results for the quarter. To participate in the call, dial 866.356.4441, passcode #56594205 at least five minutes before the start of the call. A simultaneous webcast may be accessed from the Investors tab at www.BASInc.com. The webcast will be available for replay after 2:00 p.m. EST at this same Internet address. For a telephone replay, dial 888.286.8010, passcode #58125692 after 1:00 p.m. EST.
Non-GAAP to GAAP Reconciliation
This press release contains financial measures that are not calculated in accordance with accounting principles generally accepted in the United States (GAAP). The non-GAAP financial measures are EBITDA for the first quarters of fiscal 2012 and 2013. EBITDA refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation, and amortization and/or exclude certain non-cash expenses as permitted by our credit agreements, such as stock-based compensation.
The non-GAAP financial information should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management, however, believes that these non-GAAP financial measures, when used in conjunction with the results presented in accordance with GAAP, may provide a more complete understanding of the Company's results and may facilitate a fuller analysis of the Company's results, particularly in evaluating performance from one period to another. Management has chosen to provide this supplemental information to investors, analysts, and other interested parties to enable them to perform additional analyses of results and to illustrate the results giving effect to the non-GAAP adjustments shown in the reconciliation. Management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
BIOANALYTICAL SYSTEMS, INC.
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)|
|(In thousands, except per share amounts) (Unaudited)|
|Three Months Ended|
|Cost of service revenue||3,382||5,256|
|Cost of product revenue||566||778|
|Total cost of revenue||3,948||6,034|
|Research and development||85||178|
|General and administrative||1,098||1,608|
|Total operating expenses||1,553||2,784|
|Operating income (loss)||302||(1,302||)|
|Income (loss) before income taxes||139||(1,491||)|
|Net income (loss)||$||139||$||(1,491||)|
|Other comprehensive income (loss):|
|Foreign currency translation adjustment||8||(1||)|
|Comprehensive income (loss)||$||147||$||(1,492||)|
|Basic net income (loss) per share||$||0.02||$||(0.21||)|
|Diluted net income (loss) per share||$||0.02||$||(0.21||)|
|Weighted common shares outstanding:|
BIOANALYTICAL SYSTEMS, INC.
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|(In thousands, except share amounts)|
|December 31,||September 30,|
|Cash and cash equivalents||$||670||$||721|
|Unbilled revenues and other||898||921|
|Total current assets||5,452||6,892|
|Property and equipment, net||18,167||18,628|
|Debt issue costs||10||18|
|Liabilities and shareholders' equity|
|Income tax accruals||17||17|
|Revolving line of credit||962||1,444|
|Current portion of capital lease obligation||280||330|
|Current portion of long-term debt||5,676||583|
|Total current liabilities||14,543||11,387|
|Capital lease obligation, less current portion||689||739|
|Long-term debt, less current portion||--||5,259|
Preferred shares, no par value: Authorized 1,000,000 shares, 1,335 Series A shares at $1,000 stated value issued and outstanding at Dec. 31, 2012 and at Sep. 30, 2012
Common shares, no par value: Authorized 19,000,000 shares; 7,656,718 issued and outstanding at Dec. 31, 2012 and 7,638,738 at Sep. 30, 2012
|Additional paid-in capital||20,541||20,451|
|Accumulated other comprehensive income||37||29|
|Total shareholders' equity||9,832||9,590|
|Total liabilities and shareholders' equity||$||25,064||$||26,975|
BIOANALYTICAL SYSTEMS, INC.
RECONCILIATION OF GAAP TO NON-GAAP EARNINGS
|(In thousands) (Unaudited)|
|Three Months Ended|
|GAAP Net income (loss)||
Read Full Story
From Our Partners
Recommended For You
Trump called for the legalization of all drugs in 1990 — but his cabinet signals a very different policy
More to Explore